Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fin-espam is a branded generic line of antispasmodic medications developed and marketed by the Colombian pharmaceutical company Laboratorios Laproff. The primary active ingredient is hyoscine (also known as scopolamine or hioscina), a small molecule muscarinic acetylcholine receptor antagonist. Hyoscine works by blocking the action of acetylcholine on smooth muscle cells, thereby relieving spasms in the gastrointestinal, biliary, and urinary tracts. The Fin-espam product range includes single-ingredient tablets (10 mg and 25 mg) and combination formulations such as Fin-espam Fem, which contains 20 mg of hyoscine and 400 mg of ibuprofen. This combination is specifically indicated for the treatment of dysmenorrhea, providing both antispasmodic relief and anti-inflammatory analgesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fin-espam.